UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 30.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,170,000 shares of the company's stock after purchasing an additional 272,467 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 1.42% of Editas Medicine worth $1,486,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Ieq Capital LLC acquired a new position in shares of Editas Medicine in the fourth quarter valued at $31,000. Dark Forest Capital Management LP increased its holdings in Editas Medicine by 66.9% in the 4th quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock valued at $42,000 after buying an additional 13,138 shares during the period. Freestone Grove Partners LP acquired a new position in shares of Editas Medicine in the 4th quarter valued at $46,000. Intech Investment Management LLC lifted its holdings in shares of Editas Medicine by 43.1% during the 4th quarter. Intech Investment Management LLC now owns 40,942 shares of the company's stock worth $52,000 after acquiring an additional 12,336 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Editas Medicine during the 4th quarter valued at about $90,000. Institutional investors own 71.90% of the company's stock.

Editas Medicine Trading Up 7.4%

Shares of EDIT stock traded up $0.15 during trading hours on Thursday, reaching $2.18. The company's stock had a trading volume of 3,185,499 shares, compared to its average volume of 2,577,820. Editas Medicine, Inc. has a one year low of $0.91 and a one year high of $6.22. The firm's fifty day simple moving average is $1.52 and its 200 day simple moving average is $1.52. The stock has a market capitalization of $182.49 million, a P/E ratio of -0.85 and a beta of 2.10.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.08. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The firm had revenue of $4.66 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the prior year, the firm posted ($76.00) earnings per share. As a group, equities research analysts forecast that Editas Medicine, Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on EDIT shares. Robert W. Baird dropped their target price on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Cantor Fitzgerald upgraded shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 29th. Wall Street Zen upgraded Editas Medicine from a "sell" rating to a "hold" rating in a research report on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on Editas Medicine in a research note on Monday, April 28th. They issued a "buy" rating and a $3.00 target price for the company. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $5.36.

Insider Buying and Selling at Editas Medicine

In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,192 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total value of $26,130.24. Following the completion of the sale, the chief executive officer now directly owns 280,282 shares in the company, valued at approximately $482,085.04. This trade represents a 5.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 16,364 shares of company stock worth $28,146 over the last ninety days. Company insiders own 2.10% of the company's stock.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.